INAB – in8bio, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

INAB

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

1/12

08:55 am

inab

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma [Yahoo! Finance]

Medium Report

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma [Yahoo! Finance]

Report

1/12

08:00 am

inab

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

High Report

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

Report

12/19

08:35 am

inab

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager [Yahoo! Finance]

High Report

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager [Yahoo! Finance]

Report

12/19

08:00 am

inab

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

High Report

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

Report

11/6

04:28 pm

inab

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]

Medium Report

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]

Report

11/6

04:00 pm

inab

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Medium Report

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Report

10/29

08:00 am

inab

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

Medium Report

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

Report

10/27

08:00 am

inab

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

High Report

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.